Pulmozyme

Active Ingredient(s): Dornase Alfa
FDA Approved: * December 30, 1993
Pharm Company: * GENENTECH
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Pulmozyme Overview

Dornase alfa (proprietary name Pulmozyme from Genentech) is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus of cystic fibrosis patients and reduces viscosity in the lungs, promoting improved clearance of secretions. This protein therapeutic agent is produced in Chinese hamster ovary cells. Contents 1 Cystic fibrosis 2 Contraindications 3 Economy 4 Off label us...

Read more Pulmozyme Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dornase_alfa

Recent Pulmozyme Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Pulmozyme: (1 result)

Sorted by National Drug Code

• 50242-100 Pulmozyme 1 mg/ml Respiratory (Inhalation) Solution by Genentech, Inc.

Other drugs which contain Dornase Alfa or a similar ingredient: (1 result)

• DORNASE ALFA